Evidence map›Paper›PMID 34681622›Full record

ReviewInternational journal of molecular sciences2021

The Role of Phosphatidylinositol 3-Kinase Catalytic Subunit Type 3 in the Pathogenesis of Human Cancer.

Chien-An Chu, Yi-Wen Wang, Yi-Lin Chen, Hui-Wen Chen, Jing-Jing Chuang, Hong-Yi Chang, Chung-Liang Ho, Chen Chang, Nan-Haw Chow, Chung-Ta Lee

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Mechanistic Insights into Tumorigenesis from Serum Proteins.medRxiv : the preprint server for health sciences · 2025
    Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Chien-An ChuDepartment of Pathology, College of Medicine, National Cheng Kung University, Tainan 701401, Taiwan.
Yi-Wen WangDepartment of Pathology, College of Medicine, National Cheng Kung University, Tainan 701401, Taiwan.
Yi-Lin ChenDepartment of Pathology, National Cheng Kung University Hospital, Tainan 704302, Taiwan.
Hui-Wen ChenDepartment of Pathology, National Cheng Kung University Hospital, Tainan 704302, Taiwan.
Jing-Jing ChuangDepartment of Microbiology, Immunology and Biopharmaceuticals, National Chiayi University, Chiayi 600355, Taiwan.
Hong-Yi ChangDepartment of Biotechnology and Food Technology, College of Engineering, Southern Taiwan University of Science and Technology, Tainan 710301, Taiwan.
Chung-Liang HoDepartment of Pathology, College of Medicine, National Cheng Kung University, Tainan 701401, Taiwan.
Chen ChangDepartment of Pathology, College of Medicine, National Cheng Kung University, Tainan 701401, Taiwan.
Nan-Haw ChowDepartment of Pathology, College of Medicine, National Cheng Kung University, Tainan 701401, Taiwan.
Chung-Ta LeeDepartment of Pathology, College of Medicine, National Cheng Kung University, Tainan 701401, Taiwan.
National Cheng Kung University Hospital · TWNational Cheng Kung University · TWNational Chiayi University · TWSouthern Taiwan University of Science and Technology · TW

Funding

Ministry of Science and Technology, Taiwan NSC108-2320-B-006-050-MY3Ministry of Science and Technology, Taiwan NSC110-2314-B-006-083Ministry of Science and Technology, Taiwan NSC110-2320-B-006 -026National Cheng Kung University Hospital NCKUH-10704015National Cheng Kung University Hospital NCKUH-11008004
6 · The paper itself

Abstract

Phosphatidylinositol 3-kinase catalytic subunit type 3 (PIK3C3), the mammalian ortholog of yeast vesicular protein sorting 34 (Vps34), belongs to the phosphoinositide 3-kinase (PI3K) family. PIK3C3 can phosphorylate phosphatidylinositol (PtdIns) to generate phosphatidylinositol 3-phosphate (PI3P), a phospholipid central to autophagy. Inhibition of PIK3C3 successfully inhibits autophagy. Autophagy maintains cell survival when modifications occur in the cellular environment and helps tumor cells resist metabolic stress and cancer treatment. In addition, PIK3C3 could induce oncogenic transformation and enhance tumor cell proliferation, growth, and invasion through mechanisms independent of autophagy. This review addresses the structural and functional features, tissue distribution, and expression pattern of PIK3C3 in a variety of human tumors and highlights the underlying mechanisms involved in carcinogenesis. The implications in cancer biology, patient prognosis prediction, and cancer therapy are discussed. Altogether, the discovery of pharmacological inhibitors of PIK3C3 could reveal novel strategies for improving treatment outcomes for PIK3C3-mediated human diseases.

Indexed as

AutophagyCell ProliferationClass III Phosphatidylinositol 3-KinasesDisease ProgressionGene Expression Regulation, NeoplasticHumansNeoplasmsNeoplastic Stem CellsProtein DomainsClass III Phosphatidylinositol 3-Kinasesautophagycancercolorectal cancerPIK3C3Vps34

Identifiers

PMID34681622
PMCPMC8535862
OpenAlexW3205381305

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.